Carina Biotech is an Australian company designing and developing CAR-T and other adoptive cell therapies against novel antigen targets for solid cancers. Carina has also developed a proprietary multi-functional chemokine receptor platform to enable CAR-T cell homing and access to tumours, and a CAR-T cell manufacturing platform to increase access, efficacy and persistence.
Carina’s lead program, a LGR5 CAR-T cell therapy, targets patients with metastatic colorectal cancer. LGR5 is a cancer stem cell marker that is highly expressed on advanced colorectal cancer as well as other cancers. Carina’s pre-clinical studies of the LGR5 CAR-T cell have shown highly promising results with complete tumour regression and no tumour recurrence. We are currently undertaking IND enabling studies with the aim of commencing a Phase 1/2 clinical trial later this year.
Carina’s lead program, a LGR5 CAR-T cell therapy, targets patients with metastatic colorectal cancer. LGR5 is a cancer stem cell marker that is highly expressed on advanced colorectal cancer as well as other cancers. Carina’s pre-clinical studies of the LGR5 CAR-T cell have shown highly promising results with complete tumour regression and no tumour recurrence. We are currently undertaking IND enabling studies with the aim of commencing a Phase 1/2 clinical trial later this year.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2016
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
LGR targeting CAR-T cell for colorectal cancer
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
